| Literature DB >> 33953460 |
Mahmoud Abdelnabi1, Nouran Eshak2, Abdallah Almaghraby3, Yehia Saleh3,4, Fady Gerges5, Ashraf Ahmed3.
Abstract
End-stage renal disease (ESRD) is considered an independent risk factor of cardiovascular and cerebrovascular events. This review highlights atherosclerotic risk, lipid metabolism alterations, and four studies on the use of statins in ESRD-two of which showed a statistically significant effect of statins on the primary endpoints and two of which did not. Since effects were seen with higher doses of statins, further research is needed on the protective effects of intermediate to higher doses of statins in ESRD patients. Baylor University Medical Center Proceedings.Entities:
Keywords: Cardiovascular mortality; cerebrovascular mortality; end-stage renal disease; statin therapy
Year: 2021 PMID: 33953460 PMCID: PMC8059899 DOI: 10.1080/08998280.2021.1874774
Source DB: PubMed Journal: Proc (Bayl Univ Med Cent) ISSN: 0899-8280